Wegener's granulomatosis: Clinical and laboratory results of a university hospital study of 20 patients from Turkey

Clinical Rheumatology

Volumn 25, Issue 3, 2006, Pages 358-363

  Ozbalkan, Zeynep ^a,b   Kiraz, Sedat ^a   Ozturk, M Akif ^a   Ertenli, A Ihsan ^a   Apras, Sule ^a   Calguneri, Meral ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Sehit Ismail Erez Sok   (Turkey)

Author keywords

Clinic; Laboratory; Therapy; Wegener's granulomatosis

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; MESNA; METHYLPREDNISOLONE; NITROGEN; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LONG TERM CARE; MALE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SYMPTOM; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; WEGENER GRANULOMATOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CYCLOPHOSPHAMIDE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; WEGENER GRANULOMATOSIS;

EID: 33645793766     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0057-5     Document Type: Article

References (19)

1. Keller ER, Beuge N, Latza U, De Groot K, Rudert H, Nolle B, Heller M, Gross W (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long term outcome in 155 patients. Arthritis Rheum 43(5):1021-1032
2. Keller-Reinhold E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe H, Gross WL (2002) No difference in the incidence of vasculitides between north and south Germany: First results of the German vasculitis register. Rheumatology 41:540-549
3. Abdou N, Kullman G, Hoffman GS, Sharp GC, Specks U, McDonald T, Garrity J, Goeken JA, Allen N (2002) Wegener's granulomatosis: Survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29(2):309-316
4. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116:488-498
5. Fauci AS, Haynes BF, Katz P, Wolf SM (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76-85
6. Koldingsnes W, Nossent H (2002) Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 41:572-581
7. Mahr A, Girard T, Agher R, Guillevin L (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 40:492-498
8. Koopman WJ (2001) Arthritis and allied conditions. A textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, Sect 85, pp 1667-1672
9. Luqmani R, Bacon P, Moots R, Janssen B, Pall A, Emery P et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678
10. Stone JH, Hoffman GS, Merkel PA, Min Y, Uhlfelder ML, Hellman DB et al (2001) A disease-specific activity index for Wegener's granulomatosis. Modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 44:912-920
11. Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101-1107
12. Savige J, Gillis D, Benson E et al (1999) International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111:507-13
13. Gianviti A, Trompeter RS, Barratt TM, Lythgoe MF, Dillan MJ (1996) Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child 75(3):186-190
14. Tarek MM, Hoffman G (2000) Long-term outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 25(5):1237-1240
15. Jayne DR, Lockwood CM (1993) Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336:469-472
16. Jayne DR, Chapel H, Adu D, Misbach S, O'Donoughue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93(7):433-439
17. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, Fabbrizzi F, Tenybeny J, Peter J, Shoenfeld Y (1999) Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119(3):231-238
18. Jayne DR, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35(11):1150-1153
19. Murphy EA, Fox JG, Galbraigth I, Medhole R, Jones JM, Capell HA (1993) The spectrum of disease associated with a positive ANCA. Clin Rheumatol 12(3):327-331